Seelos Therapeutics Inc (SEELQ)
0.3001
-0.19
(-39.37%)
USD |
OTCM |
Nov 22, 16:00
Seelos Therapeutics Cash from Financing (Quarterly): 0.742M for June 30, 2024
Cash from Financing (Quarterly) Chart
Historical Cash from Financing (Quarterly) Data
| Date | Value |
|---|---|
| June 30, 2024 | 0.742M |
| March 31, 2024 | 2.17M |
| December 31, 2023 | 2.323M |
| September 30, 2023 | 2.49M |
| June 30, 2023 | -2.312M |
| March 31, 2023 | 8.874M |
| December 31, 2022 | -1.888M |
| September 30, 2022 | 0.334M |
| June 30, 2022 | -0.126M |
| March 31, 2022 | 0.083M |
| December 31, 2021 | 20.24M |
| September 30, 2021 | 0.143M |
| June 30, 2021 | 57.41M |
| March 31, 2021 | 34.28M |
| December 31, 2020 | 10.94M |
| September 30, 2020 | 6.38M |
| June 30, 2020 | 0.147M |
| March 31, 2020 | 8.85M |
| December 31, 2019 | 0.064M |
| September 30, 2019 | 8.497M |
| June 30, 2019 | 1.773M |
| March 31, 2019 | 19.19M |
| December 31, 2018 | 4.112M |
| September 30, 2018 | -3.108M |
| June 30, 2018 | 3.098M |
| Date | Value |
|---|---|
| March 31, 2018 | 1.275M |
| December 31, 2017 | 0.132M |
| September 30, 2017 | 3.42M |
| June 30, 2017 | 6.078M |
| March 31, 2017 | -7.129M |
| December 31, 2016 | -0.825M |
| September 30, 2016 | 3.752M |
| June 30, 2016 | -1.115M |
| March 31, 2016 | 9.191M |
| December 31, 2015 | -0.496M |
| September 30, 2015 | 4.998M |
| June 30, 2015 | -0.099M |
| March 31, 2015 | 11.05M |
| December 31, 2014 | 4.489M |
| September 30, 2014 | 2.834M |
| June 30, 2014 | -1.041M |
| March 31, 2014 | 1.583M |
| December 31, 2013 | 0.008M |
| September 30, 2013 | -0.01M |
| June 30, 2013 | 15.84M |
| March 31, 2013 | 0.791M |
| December 31, 2012 | 1.23M |
| September 30, 2012 | 0.004M |
| June 30, 2012 | -0.002M |
| March 31, 2012 | 19.53M |
Cash From Financing Definition
Cash flow from financing is a major line item of the statement of cash flows. This metric tracks the movement of cash flows for the overall financing activities of the company. A few examples of financing activities include common stock issuance, total dividends paid, and net debt issuance.
Cash from Financing (Quarterly) Range, Past 5 Years
-2.312M
Minimum
Jun 2023
57.41M
Maximum
Jun 2021
7.954M
Average
2.17M
Median
Mar 2024
Cash from Financing (Quarterly) Benchmarks
| Cassava Sciences Inc | 0.00 |
| Bristol-Myers Squibb Co | -3.852B |
| enVVeno Medical Corp | 13.59M |
| 180 Life Sciences Corp | -0.4761M |
| NovaBay Pharmaceuticals Inc | 2.089M |
Cash from Financing (Quarterly) Related Metrics
| Cash from Operations (Quarterly) | -0.972M |
| Free Cash Flow | -13.27M |
| Free Cash Flow Per Share (Quarterly) | -6.183 |
| Free Cash Flow Yield | -50.32K% |